Merck gets approval for its CRISPR genome-editing technology in China
Category: #health  By Saipriya Iyer  Date: 2018-04-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck gets approval for its CRISPR genome-editing technology in China

Merck KGaA has declared that the Chinese Patent Office has provided it with the right to use its CRISPR gene-editing technology in the country. According to the company’s statement, the CRISPR technique helps chromosomes to alter in the living cells and is one of the modern therapies that can be used for treating many of the chronic disorders.

The firm also seems to have added that the new technology is used to determine the genes associated with cancer along with other rare ailments including reverse mutations causing blindness in the individuals. Udit Batra, CEO of Life Sciences division at Merck KGaA, has stated that the firm will license its CRISPR-linked patents to companies involved in carrying out pure scientific research activities, offering therapeutic solutions, and making use of farming technology.

As per reliable sources, Merck has filed patents for using its CRISPR technology across countries such Japan, Brazil, U.S., and India. Regions such as South Korea, Israel, Australia, Canada, Europe, and Singapore have already approved the patents for the use of CRISPR technology for treating various diseases. The firm’s forthcoming CRISPR technology patent in China includes chromosomal integration or cutting sequence of chromosomes from the eukaryotic cell tissues along with the insertion of donor DNA sequence into these Eukaryotic cells by using the gene-editing CRISPR technique.

The genome-editing technology assists the researchers to replace disease linked gene mutation with a beneficial DNA gene sequence. Merck has claimed that the CRISPR gene-editing technology can be utilized to add transgenes to the endogenous protein materials, helping them in visual tracking of the disease within the cells.

The firm, which is involved in both the deployment and supply of the genome editing CRISPR Technology, holds the view that the new technique has resulted in many of the technological breakthroughs witnessed lately across the medical and biotechnology sectors. Apparently, Merck supports the gene-editing applications and complies with the ethical & legal standards that regulate gene-editing technology.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...